CA2737392A1 - Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis - Google Patents

Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis Download PDF

Info

Publication number
CA2737392A1
CA2737392A1 CA2737392A CA2737392A CA2737392A1 CA 2737392 A1 CA2737392 A1 CA 2737392A1 CA 2737392 A CA2737392 A CA 2737392A CA 2737392 A CA2737392 A CA 2737392A CA 2737392 A1 CA2737392 A1 CA 2737392A1
Authority
CA
Canada
Prior art keywords
uric acid
lung
inflammation
fibrosis
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2737392A
Other languages
English (en)
French (fr)
Inventor
Bernhard Ryffel
Isabelle Couillin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of CA2737392A1 publication Critical patent/CA2737392A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/62—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving uric acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • Y10T436/148888—Uric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2737392A 2008-09-18 2009-09-18 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis Abandoned CA2737392A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305565.7 2008-09-18
EP08305565A EP2165705A1 (en) 2008-09-18 2008-09-18 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
PCT/EP2009/062159 WO2010031859A1 (en) 2008-09-18 2009-09-18 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis

Publications (1)

Publication Number Publication Date
CA2737392A1 true CA2737392A1 (en) 2010-03-25

Family

ID=40329393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2737392A Abandoned CA2737392A1 (en) 2008-09-18 2009-09-18 Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis

Country Status (5)

Country Link
US (1) US8569017B2 (enExample)
EP (2) EP2165705A1 (enExample)
JP (1) JP2012502962A (enExample)
CA (1) CA2737392A1 (enExample)
WO (1) WO2010031859A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102133290B1 (ko) * 2018-10-23 2020-07-13 연세대학교 산학협력단 결핵의 예방 또는 치료용 조성물
CN114746546B (zh) * 2019-10-29 2024-09-03 西湖生物医药科技(杭州)有限公司 工程化红细胞用于治疗痛风和高尿酸血症
CN115989219B (zh) * 2020-06-29 2026-02-13 贝凯恩生物医疗技术有限公司 用于治疗炎症小体介导的肺部疾病的丙磺舒化合物
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물
CN115039737B (zh) * 2021-08-09 2023-07-25 北京中医药大学 一种建立尿酸盐肾沉积动物模型的方法
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028660B1 (de) 1979-11-10 1985-10-23 Siegfried Aktiengesellschaft Xanthinoxydasehemmer und Verwendung von Benztriazinderivaten
US5021448A (en) 1990-02-22 1991-06-04 Ciba-Geigy Corporation Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
ES2309213T3 (es) 2001-11-16 2008-12-16 Nippon Chemiphar Co., Ltd. Inhibidor de xantina-oxidasa.
DK1471065T3 (da) 2002-01-28 2008-03-25 Fuji Yakuhin Co Ltd Hidtil ukendt 1,2,4-triazolforbindelse
US20070224287A1 (en) * 2003-09-26 2007-09-27 Wright Richard M Methods of Modulating Inflammatory Reactions by Modulating Xanthine Oxidoreductase Activity
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2008144616A1 (en) * 2007-05-18 2008-11-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
AU2008259768B2 (en) 2007-06-05 2013-08-29 Paka Pulmonary Pharmaceuticals, Inc. Compositions for delivering medicaments into the lungs, uses thereof

Also Published As

Publication number Publication date
EP2344149A1 (en) 2011-07-20
JP2012502962A (ja) 2012-02-02
US20110243911A1 (en) 2011-10-06
WO2010031859A1 (en) 2010-03-25
US8569017B2 (en) 2013-10-29
EP2165705A1 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
Gasse et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
Zhu et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation
Bae et al. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome
Griese et al. Inhibition of airway proteases in cystic fibrosis lung disease
US8569017B2 (en) Method for the preventing and/or treating IL-1 beta lung pathology in mammals by administering a uric acid reducing compound
Luo et al. Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway
US20130302344A1 (en) Methods and medicaments for the treatment of gout or pseudogout
Tolstanova et al. Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF
Wang et al. VX765 alleviates dextran sulfate sodium-induced colitis in mice by suppressing caspase-1-mediated pyroptosis
Wang et al. A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation
Shi et al. Pharmacological inhibition of fatty acid-binding protein 4 (FABP4) protects against renal ischemia-reperfusion injury
Shilovskiy et al. The role of interleukin-37 in the pathogenesis of allergic diseases
US20160120857A1 (en) Anti-Fibrogenic Compounds, Methods and Uses Thereof
Leng et al. C-176 inhibits macrophage polarization towards M1-subtype and ameliorates LPS induced acute kidney injury
HUP0202048A2 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
Wilkinson et al. Fatty acid nitroalkenes inhibit the inflammatory response to bleomycin-mediated lung injury
Krenn et al. Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans
Zeng et al. HMGB1 could restrict 1, 3-β-glucan induced mice lung inflammation by affecting Beclin1 and Bcl2 interaction and promoting the autophagy of epithelial cells
AU2018244275B2 (en) Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections
US8173598B2 (en) Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
US20190365689A1 (en) Use of ape/ref-1 redox specific inhibitors for treating metastatic prostate cancer
Xie et al. Targeted nuclear degranulation of neutrophils in the shock stage of severe burns drives rapid neutrophil extracellular trap release during infection to mediate acute lung injury
Devine et al. Minocycline attenuates cardiac dysfunction in tumor-burdened mice
US20220339122A1 (en) Methods for the treatment of diseases associated with dysregulated activation and recruitment of neutrophils
US11369609B2 (en) Small molecule Wnt inhibitor as treatment for dyslipidemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140721

FZDE Discontinued

Effective date: 20160919